Displaying drugs 10101 - 10125 of 11014 in total
Ensovibep
Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).
Investigational
Matched Description: … Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients …
Molybdenum cofactor
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Experimental
Matched Iupac: … 2-amino-4-oxo-8-[(phosphonatooxy)methyl]-6-sulfanidyl-3H,4H,5H,5aH,8H,9aH,10H-pyrano[3,2-g]pteridin-7- …
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Creatinolfosfate
COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease. COP has been investigated for the treatment of Diabetic Retinopathy.
Investigational
Matched Description: … COP has been investigated for the treatment of Diabetic Retinopathy. ... COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory …
Hemoximer
Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.
Investigational
Matched Description: … Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering …
Trebananib
Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.
Investigational
Matched Description: … Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian ... Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon …
Relacorilant
Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).
Investigational
Matched Description: … Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients …
KRN-5500
KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Investigational
Matched Description: … KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic …
Menaquinone
Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists).
Investigational
Matched Description: … Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients …
Norleucine
Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women).
Investigational
Matched Description: … Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in …
PEN-866
PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).
Investigational
Matched Iupac: … oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-7- …
Matched Description: … PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid …
Matched Description: … PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid …
Sudapyridine
Sudapyridine is under investigation in clinical trial NCT05824871 (Sudapyridine (WX-081) in Rr/mdr/xdr-tuberculosis Patients).
Investigational
Matched Description: … Sudapyridine is under investigation in clinical trial NCT05824871 (Sudapyridine (WX-081) in Rr/mdr/xdr-tuberculosis …
Benzquinamide
Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.
Withdrawn
Matched Description: … The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic …
CX157
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … inhibitors of this class. ... CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor ... of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A …
Tiamulin
Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs and poultry.
Vet approved
Matched Description: … Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs …
Pyrifazimine
Pyrifazimine is under investigation in clinical trial NCT04670120 (Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)).
Investigational
Matched Description: … Pyrifazimine is under investigation in clinical trial NCT04670120 (Early Bactericidal Activity Safety …
2-(aminomethyl)phenol
2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Older Adults).
Investigational
Matched Description: … in Older Adults). ... 2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study …
VB-201
VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).
Investigational
Matched Description: … VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With …
Botensilimab
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
Investigational
Matched Description: … Antibody in Advanced Cancer). ... Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal …
Betameprodine
Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of opioids,...
Experimental
Illicit
Matched Description: … Betameprodine is a structural analogue of meperidine. ... an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of ... It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, …
SEP-363856
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). SEP-363856 was developed by Sunovion pharmaceuticals....
Investigational
Matched Iupac: … methyl({[(7S)-4H,5H,7H-thieno[2,3-c]pyran-7-yl]methyl})amine …
Matched Description: … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug ... SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. ... initial clinical study has shown this drug may be effective against both positive and negative symptoms of …
Matched Description: … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug ... SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. ... initial clinical study has shown this drug may be effective against both positive and negative symptoms of …
IMCY-0141
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
Matched Description: … multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves. ... MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of …
Lortalamine
Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.
Experimental
Matched Description: … used in positron emission tomography studies to label norepinephrine transporters. ... Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. ... This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been …
Ramoplanin
Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Investigational
Matched Iupac: … 1-oxa-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46-pentadecaazacyclononatetracontan-48-yl]-2-[(2Z,4Z)-7- …
Matched Description: … Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD. …
Matched Description: … Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD. …
Lintuzumab
Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Investigational
Matched Description: … in Treating Patients With Acute Promyelocytic Leukemia). ... Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody …
Displaying drugs 10101 - 10125 of 11014 in total